Healthcare / Diagnostics & ResearchNYSE
$179.87
-2.80 (-1.53%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $5.3B · quality 81.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
31/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$127.3B
P/E
34.9x
↑EV/EBITDA
20.7x
↑ROE
6.9%
↑Gross Margin
59.1%
↑Debt/Equity
0.37
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2007–2025 · 18 años de histórico normalizado
Revenue CAGR
+4.6%
FCF CAGR
+7.3%
FCF margin
21.4%
FCF / Net income
1.46x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $24.57B · net income $3.61B · FCF $5.26B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||||
| Revenue | $24.57B | $24.57B | $23.88B | $23.89B | $26.64B | $24.80B | $22.28B | $17.91B | $17.05B | $15.52B | $16.88B | $14.43B | $12.87B | $18.28B | $18.26B | $16.09B | $12.55B | $10.52B | $12.70B | $11.03B |
| Net Income | $3.61B | $3.61B | $3.90B | $4.76B | $7.21B | $6.43B | $3.65B | $3.01B | $2.65B | $2.49B | $2.55B | $3.36B | $2.60B | $2.69B | $2.39B | $2.17B | $1.79B | $1.15B | $1.32B | $1.37B |
| EBITDA | $6.95B | $6.95B | $7.28B | $7.50B | $9.48B | $8.44B | $6.01B | $4.46B | $4.23B | $3.69B | $3.86B | $3.04B | $2.76B | $3.97B | $4.00B | $3.25B | $2.44B | $1.77B | $2.21B | — |
| EPS | 5.05 | 5.05 | 5.29 | 6.38 | 9.66 | 8.61 | 4.34 | 3.59 | 3.32 | 3.13 | 3.24 | 4.20 | 3.22 | 2.55 | 2.26 | 2.09 | 1.77 | 1.16 | 1.33 | 1.41 |
| Gross Margin | 59.1% | 59.1% | 59.5% | 58.7% | 60.8% | 61.4% | 56.0% | 55.7% | 55.8% | 55.2% | 55.3% | 53.8% | 53.2% | 51.1% | 51.6% | 50.8% | 51.0% | 48.2% | 46.8% | — |
| Operating Margin | 19.1% | 19.1% | 20.4% | 21.8% | 28.3% | 25.7% | 19.0% | 18.3% | 17.9% | 16.6% | 16.2% | 15.0% | 15.9% | 17.1% | 17.3% | 16.3% | 16.3% | 13.7% | 14.7% | 15.8% |
| Net Margin | 14.7% | 14.7% | 16.3% | 19.9% | 27.1% | 25.9% | 16.4% | 16.8% | 15.5% | 16.1% | 15.1% | 23.3% | 20.2% | 14.7% | 13.1% | 13.5% | 14.3% | 11.0% | 10.4% | 12.4% |
| Balance Sheet | ||||||||||||||||||||
| Debt/Equity | 0.37 | 0.37 | 0.35 | 0.37 | 0.41 | 0.49 | 0.53 | 0.71 | 0.34 | 0.39 | 0.42 | 0.51 | 0.15 | 0.15 | 0.28 | 0.31 | 0.20 | 0.25 | 0.26 | — |
| Current Ratio | 1.87 | 1.87 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||||||
| Free Cash Flow | $5.26B | $5.26B | $5.30B | $5.78B | $7.40B | $7.12B | $5.42B | $3.32B | $3.44B | $2.91B | $2.93B | $3.29B | $3.29B | $3.05B | $2.96B | $2.29B | $1.89B | $1.63B | $1.67B | $1.48B |
| Returns | ||||||||||||||||||||
| ROE | 6.9% | 6.9% | 7.9% | 8.9% | 14.4% | 14.2% | 9.2% | 9.9% | 9.4% | 9.5% | 11.1% | 14.2% | 11.1% | 12.0% | 12.6% | 12.9% | 13.1% | 9.9% | 13.4% | — |
| Valuation | ||||||||||||||||||||
| P/E | 34.86 | 34.86 | 44.39 | 36.10 | 23.17 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | 20.72 | 20.72 | 25.86 | 24.65 | 18.94 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 2.45 | 2.45 | 3.49 | 3.20 | 3.29 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||||||
| Revenue Growth | 2.9% | 2.9% | -0.1% | -10.3% | — | 11.3% | 24.4% | 5.1% | 9.9% | -8.1% | 17.0% | 12.2% | -29.6% | 0.1% | 13.5% | 28.2% | 19.3% | -17.2% | 15.2% | — |
| EPS Growth | -4.5% | -4.5% | -17.1% | -34.0% | — | 98.6% | 20.7% | 8.3% | 5.9% | -3.3% | -23.0% | 30.6% | 26.0% | 13.1% | 8.0% | 17.8% | 52.6% | -12.6% | -5.5% | — |
| Dividend Yield | 0.9% | 0.9% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
46.8%
EPS terminal req.
$15.96
Spread vs growth
-51.3%
5Y implied EPS CAGR
30.8%
EPS terminal req.
$19.31
Spread vs growth
-35.3%
10Y implied EPS CAGR
19.9%
EPS terminal req.
$31.10
Spread vs growth
-24.5%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-4.4%
Start / end P/E
35.9x → 35.6x
EPS bridge
5.29 → 5.05
Residual
+0.0%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.